Menin-Inhibitor Targeted Maintenance in AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Revumenib
Related studies linked through entity extraction aliases.
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Revumenib and Mezigdomide in People With Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Status
- RECRUITING
- Phase
- PHASE3
A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- Status
- RECRUITING
- Phase
- PHASE3
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
Revumenib in Combination With 7+3 + Midostaurin in AML
- Status
- RECRUITING
- Phase
- PHASE1
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
- Status
- RECRUITING
- Phase
- PHASE2
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- Status
- RECRUITING
- Phase
- PHASE1
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Expanded Access Program for Revumenib
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2